We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,177.25 +9.75 (+0.19%) Dow Futures
38,297.00 +59.00 (+0.15%) Nasdaq Futures
18,213.00 +33.75 (+0.19%) Russell 2000 Futures
2,029.50 +9.70 (+0.48%) Crude Oil
85.14 -0.52 (-0.61%) Gold
2,371.50 -2.60 (-0.11%)
ChromaDex Corporation (CDXC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.0900 |
| Open | 4.0200 |
| Bid | 3.8300 x 200 |
| Ask | 3.8500 x 200 |
| Day's Range | 3.6200 - 4.1900 |
| 52 Week Range | 1.2500 - 4.6500 |
| Volume | |
| Avg. Volume | 283,687 |
| Market Cap | 289.94M |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | May 08, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.47 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CDXC
Related Research
- ChromaDex CorporationDaily – Vickers Top Insider Picks for 04/12/2024The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat3 days agoArgus Research
Simply Wall St.Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?
ChromaDex Corporation ( NASDAQ:CDXC ), might not be a large cap stock, but it led the NASDAQCM gainers with a...
ZacksPrecision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Business WireChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
LOS ANGELES, March 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN
Simply Wall St.ChromaDex Full Year 2023 Earnings: EPS Beats Expectations
ChromaDex ( NASDAQ:CDXC ) Full Year 2023 Results Key Financial Results Revenue: US$83.6m (up 16% from FY 2022). Net...
GuruFocus.comChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA
Net Sales Rise to $83.6 Million with a Notable Gross Margin Improvement
Insider MonkeyChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript March 6, 2024 ChromaDex Corporation beats earnings expectations. Reported EPS is $0.00152, expectations were $-0.03. ChromaDex Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing […]
- Thomson Reuters StreetEvents
Q4 2023 Chromadex Corp Earnings Call
Q4 2023 Chromadex Corp Earnings Call
Business WireChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
LOS ANGELES, March 06, 2024--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.
- Simply Wall St.
Insiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company
Key Insights ChromaDex's significant retail investors ownership suggests that the key decisions are influenced by...
Business WireChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
LOS ANGELES, February 21, 2024--ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| PIRS Pieris Pharmaceuticals, Inc. | |||
| CASI CASI Pharmaceuticals, Inc. | |||
| CTMX CytomX Therapeutics, Inc. | |||
| CLSD Clearside Biomedical, Inc. | |||
| CRVS Corvus Pharmaceuticals, Inc. |
Similar to CDXC
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| ENTX Entera Bio Ltd. | |||
| VIRI Virios Therapeutics, Inc. | |||
| GALT Galectin Therapeutics Inc. | |||
| INKT MiNK Therapeutics, Inc. | |||
| NXTC NextCure, Inc. |
Analyst Price Targets (3)
Upgrades & Downgrades
| Maintains | Roth MKM: Buy to Buy | 4/9/2024 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/11/2024 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/10/2023 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/5/2023 | |
| Maintains | HC Wainwright & Co.: to Buy | 3/13/2023 | |
| Reiterates | HC Wainwright & Co.: to Buy | 2/1/2023 |
Company Profile
10900 Wilshire Blvd
Suite 600
Los Angeles, CA 90024
United States
310 388 6706
https://www.chromadex.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 106
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
